Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios
- 265 Downloads
Treatment for advanced renal cell carcinoma (RCC) has become increasingly more complex over the last several years. Objective 1 is to which treatment option is immunotherapy, targeted therapy, or the combination of immunotherapy with targeted therapy the best for patients? Objective 2 is to study which regimens with the highest chance of cure/durable response and what is the optimal sequence in advanced RCC.
Materials and methods
Between 2016 and 2018, 6 adult patients admitted to our institute with RCC were reviewed. Clinical information, treatment and outcomes were retrieved for further analysis. This applies to all risk groups as determined by the International Metastatic RCC Database Consortium criteria. We have intended to provide the reader with a comprehensive and authoritative review of the broad subject of RCC.
Immunotherapy-based regimens and the functioning of various growth-and survival-promoting kinases, specifically, receptor-associated tyrosine kinases have dramatically changed the treatment landscape of advanced RCC. Recent phase III trials have demonstrated a survival benefit for front-line ipilimumab plus nivolumab therapy, and immune checkpoint inhibition plus anti-vascular endothelial growth factor combination therapy in metastatic clear-cell RCC.
In renal cell carcinoma, rapid and successful drug development has resulted in multiple treatment options, requiring careful decision making for individual patients and have emphasized how newly developed therapies work.
KeywordsMetastatic renal cell carcinoma Tyrosine kinase inhibitors Immunotherapy
Compliance with ethical standards
Conflict of interest
All authors declare no conflict of interest
Research involving human participants and/or animals
This article does not contain any studies with human participants performed by any of the authors.
- 1.Linehan WM, Pinto PA, Srinivasan R, Merino M, Choyke P, Choyke L et al (2007) Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res 13:671–679Google Scholar
- 6.Bex A, van der Veldt AA, Blank C, van den Eertwegh AJ, Boven E, Horenblas S et al (2009) Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol 27(4):533–539PubMedGoogle Scholar
- 14.Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R (2001) European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal- cell carcinoma: a randomised trial. Lancet 358(9286):966–970Google Scholar
- 16.Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU et al (2018) Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol 5:167–170 (Epub ahead of print) Google Scholar
- 17.Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN et al (2013) External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 14(2):141–148PubMedPubMedCentralGoogle Scholar
- 18.Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J et al (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369(8):722–731Google Scholar
- 20.Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK et al (2017) Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN Trial. J Clin Oncol 35(6):591–597PubMedGoogle Scholar
- 22.McDermott DF, Lee JL, Szczylik C, Donskov F, Malik J, Alekseev BY et al (2018) Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma: results from cohort A of KEYNOTE-427. J Clin Oncol 36S:ASCO#4500Google Scholar
- 23.Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S et al (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2(10):1096–1103Google Scholar
- 26.Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS et al (2014) Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 201420(6):607–615Google Scholar
- 28.Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S et al (2016) Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun 30(7):12624Google Scholar
- 33.Motzer R, Powles T, Atkins M, Escudier B, McDermott DF, Suarez C et al (2018) IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma. J Clin Oncol 36:578 (Abstract 578) Google Scholar
- 36.Rini BI, Huseni M, Atkins MB, McDermott DF, Powles TB, Escudier B et al (2018) Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): results from a Phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC). Ann Oncol. https://doi.org/10.1093/annonc/mdy424.037 CrossRefGoogle Scholar
- 46.Ravaud A, Oudard S, De Fromont M, Chevreau C, Gravis G, Zanetta S et al (2015) First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†. Ann Oncol 26:1123–1128PubMedGoogle Scholar